TNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Tango Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$23.53+1.49 (+6.76%)
Close on Oct 19, 2026
- Market cap
- $3.53B
- P/E (TTM)
- –
- Dividend yield
- –
Tango Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| Collaboration Revenue [Member] | $62.38M | $29.97M | $31.53M | $24.86M | $26.04M | $6.97M | 100.0% | +108.2% |
| License Revenue [Member] | – | $12.10M | $5.00M | – | $11.00M | $684.00K | – | – |
By region
From the segment and revenue-disaggregation notes of Tango Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.